# Incyte Corporation clinical trials: 288 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 288 trials with Incyte Corporation as lead sponsor, 31 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Incyte Corporation: 288 rows for $14.40, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/incyte-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 288
- Recruiting or not yet: 31
- Read on: November 19, 2026

## Trials

The 25 newest of 288, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 7, 2026 | NCT07862998 | A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable... | Incyte Corporation | Phase 2 | Not yet recruiting | Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862998) |
| October 2, 2026 | NCT07854249 | A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on... | Incyte Corporation | Phase 1 | Not yet recruiting | Renal Insufficiency, Kidney Diseases | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854249) |
| October 1, 2026 | NCT07853040 | A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment | Incyte Corporation | Phase 1 | Recruiting | Hepatic Insufficiency, Liver Diseases | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853040) |
| September 16, 2026 | NCT07823322 | A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After... | Incyte Corporation | Phase 2 | Recruiting | CRC (Colorectal Cancer) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823322) |
| September 11, 2026 | NCT07814404 | A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of \[14C\]-INCB161734 in Healthy Male... | Incyte Corporation | Phase 1 | Completed | Healthy Participants | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814404) |
| September 1, 2026 | NCT07797283 | Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing... | Incyte Corporation | Phase 3 | Not yet recruiting | Ovarian Cancer | 590 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797283) |
| June 3, 2026 | NCT07623200 | A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia | Incyte Corporation | Phase 3 | Recruiting | Essential Thrombocythemia | 426 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623200) |
| May 14, 2026 | NCT07588139 | A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical... | Incyte Corporation | Phase 1 | Completed | Healthy Participants | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588139) |
| April 30, 2026 | NCT07559474 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe... | Incyte Corporation | Phase 1 | Recruiting | Hepatic Insufficiency, Liver Diseases | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559474) |
| April 30, 2026 | NCT07559396 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment... | Incyte Corporation | Phase 1 | Recruiting | Renal Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559396) |
| April 13, 2026 | NCT07522073 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal... | Incyte Corporation | Phase 3 | Recruiting | Solid Tumors | 588 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07522073) |
| March 4, 2026 | NCT07448155 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in... | Incyte Corporation | Phase 1 | Active not recruiting | Healthy Participants | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07448155) |
| March 2, 2026 | NCT07441694 | Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Incyte Corporation | Phase 1 | Recruiting | Myeloproliferative Neoplasms | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441694) |
| December 16, 2025 | NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line... | Incyte Corporation | Phase 3 | Recruiting | CRC (Colorectal Cancer) | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284849) |
| October 20, 2025 | NCT07218744 | Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of \[14C\]-INCB123667 in Healthy Male... | Incyte Corporation | Phase 1 | Completed | Healthy Participants | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218744) |
| October 9, 2025 | NCT07214779 | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With... | Incyte Corporation | Phase 3 | Active not recruiting | Ovarian Cancer | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214779) |
| October 9, 2025 | NCT07213973 | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | Incyte Corporation | Phase 2 | Recruiting | Hidradenitis Suppurativa (HS) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213973) |
| September 29, 2025 | NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | Incyte Corporation | Phase 1 | Recruiting | Solid Tumors, Hematologic Malignancies | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07195916) |
| August 15, 2025 | NCT07124078 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at... | Incyte Corporation | Phase 2 | Recruiting | Chronic Graft-versus-host-disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07124078) |
| August 5, 2025 | NCT07104565 | Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | Incyte Corporation | Phase 2 | Recruiting | Immune Thrombocytopenia | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07104565) |
| July 3, 2025 | NCT07049575 | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | Incyte Corporation | Phase 1 | Recruiting | Hidradenitis Suppurativa | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07049575) |
| June 26, 2025 | NCT07039929 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants | Incyte Corporation | Phase 1 | Terminated | Healthy Participants | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07039929) |
| June 17, 2025 | NCT07023627 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Incyte Corporation | Phase 2 | Recruiting | Ovarian Cancer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07023627) |
| June 12, 2025 | NCT07018635 | A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in... | Incyte Corporation | Phase 1 | Completed | Healthy Participants | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07018635) |
| June 6, 2025 | NCT07008118 | A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Incyte Corporation | Phase 1 | Recruiting | Myeloproliferative Neoplasms | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07008118) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 80 |
| Phase 1/2 | 34 |
| Phase 2 | 94 |
| Phase 2/3 | 2 |
| Phase 3 | 60 |
| Phase 4 | 1 |
| Not applicable | 10 |
| Observational | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 144 |
| Terminated | 68 |
| Recruiting | 28 |
| Active not recruiting | 25 |
| Withdrawn | 10 |
| No longer available | 5 |
| Approved for marketing | 3 |
| Not yet recruiting | 3 |
| Available | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Myeloproliferative Disorders | 25 |
| Carcinoma, Non-Small-Cell Lung | 24 |
| Primary Myelofibrosis | 23 |
| Colorectal Neoplasms | 18 |
| Dermatitis, Atopic | 16 |
| Melanoma | 14 |
| Lymphoma, Large B-Cell, Diffuse | 13 |
| Skin Diseases | 13 |
| Neoplasm Metastasis | 13 |
| Lymphoma | 13 |
| Ovarian Neoplasms | 12 |
| Hidradenitis Suppurativa | 12 |
| Carcinoma, Renal Cell | 11 |
| Lymphoma, Non-Hodgkin | 11 |
| Lung Neoplasms | 11 |
| Parkinson Disease 4, Autosomal Dominant Lewy Body | 11 |
| Bronchiolitis Obliterans Syndrome | 11 |
| Pancreatic Neoplasms | 10 |
| Breast Neoplasms | 10 |
| Pruritus | 10 |
| Eczema | 10 |
| Graft vs Host Disease | 9 |
| Carcinoma, Hepatocellular | 9 |
| Hematologic Neoplasms | 8 |
| Squamous Cell Carcinoma of Head and Neck | 8 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [South African restaurants in the United States](https://specstream.ai/data/businesses/south-african-restaurants/united-states)
- [Bottled water companies in the United States](https://specstream.ai/data/businesses/bottled-water-companies/united-states)
- [Hardware and fastener manufacturers in the United States](https://specstream.ai/data/businesses/hardware-and-fastener-manufacturers/united-states)
- [Private investigators in the United States](https://specstream.ai/data/businesses/private-investigators/united-states)
- [Argentine restaurants in the United States](https://specstream.ai/data/businesses/argentine-restaurants/united-states)
- [Entertainment law firms in the United States](https://specstream.ai/data/businesses/entertainment-law-firms/united-states)
